[News] Axitinib combination therapies versus sunitinib for renal cell carcinoma

Leggi l'articolo originale


Two phase 3 trials in patients with advanced renal cell carcinoma have shown that treatment with anti-PD-1 or PD-L1 inhibitors plus axitinib result in improved progression-free survival, compared with sunitinib alone.

Lascia un commento